BenevolentAI to delist from Euronext and merge into Osaka Holdings
AMSTERDAM: BenevolentAI (Euronext Amsterdam: BAI), a leader in AI-driven drug discovery, announced plans to delist from Euronext Amsterdam via a merger with Osaka Holdings S.à...
BenevolentAI refocuses business strategy, cuts workforce by 30%
Amsterdam-based biopharma AI leader BenevolentAI announced a strategic shift to concentrate on AI-driven drug discovery and proprietary pipeline revenue streams. The decision follows the discontinuation...
BenevolentAI appoints Dr. Joerg Moeller as new CEO
BenevolentAI, a leading AI-powered biopharma company, announced today that Dr. Joerg Moeller, a veteran in the pharmaceutical industry, has joined the company as its new...
BenevolentAI announces strategic plan to boost AI and biopharma businesses
AMSTERDAM: BenevolentAI, a leader that combines cutting-edge Artificial Intelligence (AI) and science to accelerate biopharma discovery and development, today announced a strategic review approved by...